Management and 1‐Year Outcomes of Patients With Newly Diagnosed Atrial Fibrillation and Chronic Kidney Disease: Results From the Prospective GARFIELD‐AF Registry

Research output: Contribution to journalJournal articlepeer-review

Standard

Management and 1‐Year Outcomes of Patients With Newly Diagnosed Atrial Fibrillation and Chronic Kidney Disease : Results From the Prospective GARFIELD‐AF Registry. / GARFIELD‐AF.

In: Journal of the American Heart Association, Vol. 8, No. 3, 010510, 2019.

Research output: Contribution to journalJournal articlepeer-review

Harvard

GARFIELD‐AF 2019, 'Management and 1‐Year Outcomes of Patients With Newly Diagnosed Atrial Fibrillation and Chronic Kidney Disease: Results From the Prospective GARFIELD‐AF Registry', Journal of the American Heart Association, vol. 8, no. 3, 010510. https://doi.org/10.1161/JAHA.118.010510

APA

GARFIELD‐AF (2019). Management and 1‐Year Outcomes of Patients With Newly Diagnosed Atrial Fibrillation and Chronic Kidney Disease: Results From the Prospective GARFIELD‐AF Registry. Journal of the American Heart Association, 8(3), [010510]. https://doi.org/10.1161/JAHA.118.010510

Vancouver

GARFIELD‐AF. Management and 1‐Year Outcomes of Patients With Newly Diagnosed Atrial Fibrillation and Chronic Kidney Disease: Results From the Prospective GARFIELD‐AF Registry. Journal of the American Heart Association. 2019;8(3). 010510. https://doi.org/10.1161/JAHA.118.010510

Author

GARFIELD‐AF. / Management and 1‐Year Outcomes of Patients With Newly Diagnosed Atrial Fibrillation and Chronic Kidney Disease : Results From the Prospective GARFIELD‐AF Registry. In: Journal of the American Heart Association. 2019 ; Vol. 8, No. 3.

Bibtex

@article{a3f1e79da7ff4fae88a438ef6d7ecad3,
title = "Management and 1‐Year Outcomes of Patients With Newly Diagnosed Atrial Fibrillation and Chronic Kidney Disease: Results From the Prospective GARFIELD‐AF Registry",
abstract = "BackgroundUsing data from the GARFIELD‐AF (Global Anticoagulant Registry in the FIELD–Atrial Fibrillation), we evaluated the impact of chronic kidney disease (CKD) stage on clinical outcomes in patients with newly diagnosed atrial fibrillation (AF).Methods and ResultsGARFIELD‐AF is a prospective registry of patients from 35 countries, including patients from Asia (China, India, Japan, Singapore, South Korea, and Thailand). Consecutive patients enrolled (2013–2016) were classified with no, mild, or moderate‐to‐severe CKD, based on the National Kidney Foundation's Kidney Disease Outcomes Quality Initiative guidelines. Data on CKD status and outcomes were available for 33 024 of 34 854 patients (including 9491 patients from Asia); 10.9% (n=3613) had moderate‐to‐severe CKD, 16.9% (n=5595) mild CKD, and 72.1% (n=23 816) no CKD. The use of oral anticoagulants was influenced by stroke risk (ie, post hoc assessment of CHA2DS2‐VASc score), but not by CKD stage. The quality of anticoagulant control with vitamin K antagonists did not differ with CKD stage. After adjusting for baseline characteristics and antithrombotic use, both mild and moderate‐to‐severe CKD were independent risk factors for all‐cause mortality. Moderate‐to‐severe CKD was independently associated with a higher risk of stroke/systemic embolism, major bleeding, new‐onset acute coronary syndrome, and new or worsening heart failure. The impact of moderate‐to‐severe CKD on mortality was significantly greater in patients from Asia than the rest of the world (P=0.001).ConclusionsIn GARFIELD‐AF, moderate‐to‐severe CKD was independently associated with stroke/systemic embolism, major bleeding, and mortality. The effect of moderate‐to‐severe CKD on mortality was even greater in patients from Asia than the rest of the world.",
author = "Nielsen, {J{\o}rn Dalsgaard} and Chen, {K. N.} and Zhang, {H. Q.} and J. Chen and Yang, {Y. J.} and Li, {W. H.} and Yin, {Y. H.} and Chen, {Y. M.} and He, {S. H.} and Wang, {Y. (yong)} and X. Li and Chen, {M. S.} and Y. Guo and Wang, {F. Z.} and H. Li and Yang, {Z. M.} and J. Chen and X. Chen and He, {X. A.} and Hu, {X. S.} and Huang, {X. F.} and B. Li and L. Li and Liu, {T. T.} and Liu, {Y. Y.} and Ma, {T. Y.} and Shi, {X. J.} and L. Wang and Xu, {R. Y.} and Yang, {J. S.} and Yang, {Y. J.} and Y. Ye and Q. Zhang and Y. Zhang and Zheng, {W. Y.} and B. Zhou and Zhu, {X. Y.} and Nakamura, {T. (tsugihiro)} and T. Taguchi and T. Goto and J. Kim and Suzuki, {S. (susumu)} and Suzuki, {S. (susumu)} and Y. Suzuki and Chen, {D. D.} and Lee, {Y. M.} and H. Li and Lim, {W. T.} and J. Kim and Lim, {H. E.} and S. Han and Jang, {E. M.} and J. Kim and Kim, {M. S.} and Lee, {K. R.} and Lee, {K. R.} and Lee, {S. H.} and Lee, {S. H.} and V. Hansen and {Da Silva}, {L. S.} and Pereira, {V. L.} and M. Winkler and H. Nielsen and S. Husted and S. Rasmussen and P. Simonsen and M. Bruun and Helena Dominguez and K. Skagen and K. Egstrup and C. Ellervik and E. Eriksen and L. Jensen and M. Jensen and M. Schou and A. Therkelsen and K. Vesterager and D. Reimer and K. M{\"u}ller and M. Hahn and K. Schmidt and S. Sommer and S. Rasmussen and GARFIELD‐AF",
year = "2019",
doi = "10.1161/JAHA.118.010510",
language = "English",
volume = "8",
journal = "Journal of the American Heart Association",
issn = "2047-9980",
publisher = "Wiley-Blackwell",
number = "3",

}

RIS

TY - JOUR

T1 - Management and 1‐Year Outcomes of Patients With Newly Diagnosed Atrial Fibrillation and Chronic Kidney Disease

T2 - Results From the Prospective GARFIELD‐AF Registry

AU - Nielsen, Jørn Dalsgaard

AU - Chen, K. N.

AU - Zhang, H. Q.

AU - Chen, J.

AU - Yang, Y. J.

AU - Li, W. H.

AU - Yin, Y. H.

AU - Chen, Y. M.

AU - He, S. H.

AU - Wang, Y. (yong)

AU - Li, X.

AU - Chen, M. S.

AU - Guo, Y.

AU - Wang, F. Z.

AU - Li, H.

AU - Yang, Z. M.

AU - Chen, J.

AU - Chen, X.

AU - He, X. A.

AU - Hu, X. S.

AU - Huang, X. F.

AU - Li, B.

AU - Li, L.

AU - Liu, T. T.

AU - Liu, Y. Y.

AU - Ma, T. Y.

AU - Shi, X. J.

AU - Wang, L.

AU - Xu, R. Y.

AU - Yang, J. S.

AU - Yang, Y. J.

AU - Ye, Y.

AU - Zhang, Q.

AU - Zhang, Y.

AU - Zheng, W. Y.

AU - Zhou, B.

AU - Zhu, X. Y.

AU - Nakamura, T. (tsugihiro)

AU - Taguchi, T.

AU - Goto, T.

AU - Kim, J.

AU - Suzuki, S. (susumu)

AU - Suzuki, S. (susumu)

AU - Suzuki, Y.

AU - Chen, D. D.

AU - Lee, Y. M.

AU - Li, H.

AU - Lim, W. T.

AU - Kim, J.

AU - Lim, H. E.

AU - Han, S.

AU - Jang, E. M.

AU - Kim, J.

AU - Kim, M. S.

AU - Lee, K. R.

AU - Lee, K. R.

AU - Lee, S. H.

AU - Lee, S. H.

AU - Hansen, V.

AU - Da Silva, L. S.

AU - Pereira, V. L.

AU - Winkler, M.

AU - Nielsen, H.

AU - Husted, S.

AU - Rasmussen, S.

AU - Simonsen, P.

AU - Bruun, M.

AU - Dominguez, Helena

AU - Skagen, K.

AU - Egstrup, K.

AU - Ellervik, C.

AU - Eriksen, E.

AU - Jensen, L.

AU - Jensen, M.

AU - Schou, M.

AU - Therkelsen, A.

AU - Vesterager, K.

AU - Reimer, D.

AU - Müller, K.

AU - Hahn, M.

AU - Schmidt, K.

AU - Sommer, S.

AU - Rasmussen, S.

AU - GARFIELD‐AF

PY - 2019

Y1 - 2019

N2 - BackgroundUsing data from the GARFIELD‐AF (Global Anticoagulant Registry in the FIELD–Atrial Fibrillation), we evaluated the impact of chronic kidney disease (CKD) stage on clinical outcomes in patients with newly diagnosed atrial fibrillation (AF).Methods and ResultsGARFIELD‐AF is a prospective registry of patients from 35 countries, including patients from Asia (China, India, Japan, Singapore, South Korea, and Thailand). Consecutive patients enrolled (2013–2016) were classified with no, mild, or moderate‐to‐severe CKD, based on the National Kidney Foundation's Kidney Disease Outcomes Quality Initiative guidelines. Data on CKD status and outcomes were available for 33 024 of 34 854 patients (including 9491 patients from Asia); 10.9% (n=3613) had moderate‐to‐severe CKD, 16.9% (n=5595) mild CKD, and 72.1% (n=23 816) no CKD. The use of oral anticoagulants was influenced by stroke risk (ie, post hoc assessment of CHA2DS2‐VASc score), but not by CKD stage. The quality of anticoagulant control with vitamin K antagonists did not differ with CKD stage. After adjusting for baseline characteristics and antithrombotic use, both mild and moderate‐to‐severe CKD were independent risk factors for all‐cause mortality. Moderate‐to‐severe CKD was independently associated with a higher risk of stroke/systemic embolism, major bleeding, new‐onset acute coronary syndrome, and new or worsening heart failure. The impact of moderate‐to‐severe CKD on mortality was significantly greater in patients from Asia than the rest of the world (P=0.001).ConclusionsIn GARFIELD‐AF, moderate‐to‐severe CKD was independently associated with stroke/systemic embolism, major bleeding, and mortality. The effect of moderate‐to‐severe CKD on mortality was even greater in patients from Asia than the rest of the world.

AB - BackgroundUsing data from the GARFIELD‐AF (Global Anticoagulant Registry in the FIELD–Atrial Fibrillation), we evaluated the impact of chronic kidney disease (CKD) stage on clinical outcomes in patients with newly diagnosed atrial fibrillation (AF).Methods and ResultsGARFIELD‐AF is a prospective registry of patients from 35 countries, including patients from Asia (China, India, Japan, Singapore, South Korea, and Thailand). Consecutive patients enrolled (2013–2016) were classified with no, mild, or moderate‐to‐severe CKD, based on the National Kidney Foundation's Kidney Disease Outcomes Quality Initiative guidelines. Data on CKD status and outcomes were available for 33 024 of 34 854 patients (including 9491 patients from Asia); 10.9% (n=3613) had moderate‐to‐severe CKD, 16.9% (n=5595) mild CKD, and 72.1% (n=23 816) no CKD. The use of oral anticoagulants was influenced by stroke risk (ie, post hoc assessment of CHA2DS2‐VASc score), but not by CKD stage. The quality of anticoagulant control with vitamin K antagonists did not differ with CKD stage. After adjusting for baseline characteristics and antithrombotic use, both mild and moderate‐to‐severe CKD were independent risk factors for all‐cause mortality. Moderate‐to‐severe CKD was independently associated with a higher risk of stroke/systemic embolism, major bleeding, new‐onset acute coronary syndrome, and new or worsening heart failure. The impact of moderate‐to‐severe CKD on mortality was significantly greater in patients from Asia than the rest of the world (P=0.001).ConclusionsIn GARFIELD‐AF, moderate‐to‐severe CKD was independently associated with stroke/systemic embolism, major bleeding, and mortality. The effect of moderate‐to‐severe CKD on mortality was even greater in patients from Asia than the rest of the world.

U2 - 10.1161/JAHA.118.010510

DO - 10.1161/JAHA.118.010510

M3 - Journal article

C2 - 30717616

VL - 8

JO - Journal of the American Heart Association

JF - Journal of the American Heart Association

SN - 2047-9980

IS - 3

M1 - 010510

ER -

ID: 222094491